What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

Table 1 Models for end-stage liver disease score group: Liver function, hepatitis B virus DNA load, length of treatment and mortality rate

n = 24	Total bilirubin (μmol/L)	INR	Prothrombin activity (%)	Blood creatinine (μmol/L)	MELD score	HBV DNA loads (copies log10/mL)	Treatment course (d)	Mortality (%)
High model (n = 24)
Before treatment	563.8 ± 163.0	4.14 ± 1.05	21.2 ± 5.8	124.0 ± 113.1	35.97 ± 4.87	4.882 ± 1.847	17.2 ± 16.5	95.83 (23/24)
Before death	615.3 ± 216.4	4.67 ± 1.71	20.0 ± 8.1	179.1 ± 129.1b	40.48 ± 8.17	3.685 ± 1.436
t value	-1.742	-1.699	0.738	-3.340	-2.762	2.590
P value	0.095	0.103	0.468	0.003	0.011	0.027
Intermediate model (n = 54)
Before treatment	444.5 ± 160.3	2.56 ± 0.71	35.6 ± 12.1	70.1 ± 15.8	25.87 ± 2.33	6.308 ± 1.607	54.0 ± 43.2	51.85 (28/54)
After treatment	409.5 ± 357.7	3.23 ± 2.26	38.4 ± 24.1	93.4 ± 75.8	25.82 ± 13.92	3.473 ± 2.097b
t value	0.667	-2.637	-1.132	-2.223	-0.030	8.826
P value	0.508	0.011	0.263	0.031	0.976	0.000
Low model (n = 31)
Before treatment	351.9 ± 114.8	1.59 ± 0.37	56.8 ± 14.1	62.5 ± 11.1	18.88 ± 2.44	5.741 ± 1.734	66.1 ± 41.9	3.23 (1/31)
Recovery stage	102.8 ± 144.4	1.55 ± 0.64	63.5 ± 18.2	67.4 ± 52.6	12.39 ± 7.80	2.657 ± 1.154
t value	7.065	0.411	-2.468	-0.526	4.860	9.332
P value	0.000	0.684	0.020	0.603	0.000	0.000

Before death meaning: laboratory findings before articulo mortis.

^bP < 0.01 vs before treatment. MELD: Model for end-stage liver disease; HBV: Hepatitis B virus; INR: International normalized ratio.